Otwarty dostęp

Serum Uric Acid Concentration in Overweight and Obese Women with Polycystic Ovary Syndrome / Nivelul acidului uric la femeile supraponderale și obeze cu sindromul ovarelor polichistice


Zacytuj

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745-9. DOI: 10.1210/jc.2003-03204610.1210/jc.2003-03204615181052Search in Google Scholar

2. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85(7):2434-8. DOI: 10.1210/jc.85.7.2434 DOI: 10.1210/jcem.85.7.668210.1210/jc.85.7.2434Search in Google Scholar

3. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223-6. DOI: 10.1056/NEJMra04153610.1056/NEJMra04153615788499Search in Google Scholar

4. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853-61. DOI: 10.1056/ NEJM19950928333130710.1056/NEJM1995092833313077651477Search in Google Scholar

5. Harwood K, Vuguin P, DiMartino-Nardi J. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm Res. 2007;68(5):209-17. DOI: 10.1159/00010153810.1159/000101538428725217426408Search in Google Scholar

6. Kousta E, Tolis G, Franks S. Polycystic ovary syndrome. Revised diagnostic criteria and long-term health consequences. Hormones 2002;4(3):133-147. DOI: 10.14310/horm.2002.1115110.14310/horm.2002.1115116613823Search in Google Scholar

7. Cucuianu M, Brudasca I. Gout, hyperuricemia and the metabolic syndrome. Rev Romana Med Lab. 2012;20(3):199-206.Search in Google Scholar

8. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25:39-42. DOI: 10.1016/j.semnephrol. 2004.09.007Search in Google Scholar

9. Vuonnen-Markkola H, Yki-Jamnen H. Hyperuncemia and insulin resistance. J Clin Endocrinol Metab. 1995;78:25-9. DOI: 10.1210/jcem.78.1.828870910.1210/jcem.78.1.82887098288709Search in Google Scholar

10. Antilla L, Rouru J, Penttila T, Irjala K. Normal serum uric acid concentrations in women with polycystic ovary syndrome. Hum Reprod. 1996;11:2405-7. DOI: 10.1093/oxfordjournals.humrep.a01912410.1093/oxfordjournals.humrep.a0191248981120Search in Google Scholar

11. Luque-Ramirez M, Alvarez-Blasco F, Uriol Rivera MG, Escobar-Morreale HF. Serum uric acid concentration as a non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. Hum Rep. 2008;23(7):1594-601. DOI: 10.1093/humrep/den09510.1093/humrep/den09518375410Search in Google Scholar

12. Quinonez Zarza C, Silva Ruiz R, Torres Juarez JM. Obesity, arterial hypertension, metabolic disorders, and polycystic ovary syndrome. Ginecol Obstet Mex. 2000;68:317-22.Search in Google Scholar

13. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. DOI: 10.1016/j.fertnstert.2003.10.00410.1016/j.fertnstert.2003.10.00414711538Search in Google Scholar

14. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005;118:816-26. DOI: 10.1016/j.amjmed.2005.03.04310.1016/j.amjmed.2005.03.04316084170Search in Google Scholar

15. Johnson R, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183-90. DOI: 10.1161/01.HYP.0000069700.62727.C510.1161/01.HYP.0000069700.62727.C512707287Search in Google Scholar

16. Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, et al. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004;94:932-5. DOI: 10.1016/j.amjcard. 2004.06.032Search in Google Scholar

17. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106:221-6. DOI: 10.1161/01.CIR.0000022140.61460.1D10.1161/01.CIR.0000022140.61460.1D12105162Search in Google Scholar

18. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981-1030. DOI: 10.1210/er.2011-103410.1210/er.2011-1034539315523065822Search in Google Scholar

19. Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98:E628-37. DOI: 10.1210/jc.2012-390810.1210/jc.2012-390823476073Search in Google Scholar

20. Di Sarra D, Tosi F, Bonin C, Fiers T, Kaufman JM, Signori C, et al. Metabolic inflexibility is a feature of women with polycystic ovary syndrome and is associated with both insulin resistance and hyperandrogenism. J Clin Endocrinol Metab. 2013;98:2581-8. DOI: 10.1210/jc.2013-116110.1210/jc.2013-116123596136Search in Google Scholar

21. Amato MC, Galluzzo A, Finocchiaro S, Criscimanna A, Giordano C. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome. Clin Endocrinol (Oxf). 2008;69(1):52-60. DOI: 10.1111/j.1365-2265.2007.03145.x10.1111/j.1365-2265.2007.03145.x18034780Search in Google Scholar

22. Ketel IJG, Stehouwer CDA, Serne EH, Korsen TJM, Hompes PGA, Smulders YM, et al. Obese but not normal- weight women with polycystic ovary syndrome are characterized by metabolic and microvascular insulin resistance. J Clin Endocrinol Metab. 2008;93(3):3365-72. DOI: 10.1210/jc.2008-062610.1210/jc.2008-062618593766Search in Google Scholar

23. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv. 2004;59(2):141-54. DOI: 10.1097/01.OGX.0000109523.25076.E210.1097/01.OGX.0000109523.25076.E214752302Search in Google Scholar

24. Tsilchorozidou T, Overton C, Conway G. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol. 2004;60(1):335-45. DOI: 10.1046/j.1365-2265.2003.01842.x10.1046/j.1365-2265.2003.01842.x14678281Search in Google Scholar

25. Dokras A. Cardiovascular disease risk in women with PCOS. Steroids. 2013;78(8):773-6. DOI: 10.1016/j.steroids. 2013.04.009Search in Google Scholar

26. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(4):1357-63. DOI: 10.1210/jc.2005-243010.1210/jc.2005-2430Search in Google Scholar

27. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: result of a 31 year follow-up study. Hum Fertil. 2000;3(2):101-5. DOI: 10.1080/146472700200019878110.1080/1464727002000198781Search in Google Scholar

28. Meyer ML, Malek AM, Wild RA, Korytkowski MT, Talbott EO. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(2):112-26. DOI: 10.1093/humupd/dmr04610.1093/humupd/dmr046Search in Google Scholar

29. Vryonidou A, Papatheodorou A, Tavridou A. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(5):2740-6. DOI: 10.1210/jc.2004-236310.1210/jc.2004-2363Search in Google Scholar

30. Rizzo M, Berneis K, Herberger M, Pepe I, Di Fede G, Rini GB, et al. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod. 2009;24(9):2286-92. DOI: 10.1093/humrep/dep12110.1093/humrep/dep121Search in Google Scholar

31. Barber TM, McCarthy MI, Wass AH, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol. 2006;65(2):137-45. DOI: 10.1111/j.1365-2265.2006.02587.x10.1111/j.1365-2265.2006.02587.xSearch in Google Scholar

32. Alexander CJ, Tangchitnob EP, Lepor NE. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol. 2009;2(4):232-9.Search in Google Scholar

33. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulinresistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38(9):1165-74. DOI: 10.2337/diabetes.38.9.1165 DOI: 10.2337/diab.38.9.116510.2337/diabetes.38.9.1165Search in Google Scholar

34. Sathyapalan T, Atkin SL. Mediators of inflammation in polycystic ovary syndrome in relation to adiposity. Mediators of inflammation vol. 2010, article ID 758656, doi:10.1155/2010/758656 Hindawi Publishing Corporation. DOI: 10.1155/2010/75865610.1155/2010/758656Search in Google Scholar

35. Chen X, Jia X, Qiaol J, Guan Y, Kang J. Adipokines in reproductive function: a link between obesity and polycystic ovary syndrome. J Mol Endocrinol. 2013;50:R21-R37. DOI: 10.1530/JME-12-024710.1530/JME-12-0247Search in Google Scholar

36. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol. 2002;2:126-30. DOI: 10.1016/S1471-4892(02)00143-110.1016/S1471-4892(02)00143-1Search in Google Scholar

37. Vizzotto L, Vartemati M, Marinello E, Leoncini R, Pagani R, Pizzichini M. Effect of testosterone on purine metabolism and morphometric parameters in the rat liver. Mol Cell Endocrinol. 1996;119:123-7. DOI: 10.1016/0303-7207(96)03797-510.1016/0303-7207(96)03797-5Search in Google Scholar

38. Marinello E, Leoncini R, Terzouli L, Vannoni D, Porcelli B, Resconi G. Effect of testosterone on purine nucleotide metabolism in rat liver. Horm Metab Res. 2004;36:614-9. DOI: 10.1055/s-2004-82592310.1055/s-2004-82592315486812Search in Google Scholar

39. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow- up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000;283(18):2404-10. DOI: 10.1001/jama.283.18.2404 10.1001/jama.283.18.240410815083Search in Google Scholar

eISSN:
2284-5623
Język:
Angielski
Częstotliwość wydawania:
4 razy w roku
Dziedziny czasopisma:
Life Sciences, Molecular Biology, Biochemistry, Human Biology, Microbiology and Virology